In Reply We thank Messori and Clark et al for their letters. Messori asked us to comment on whether treatment-related adverse events cost more for repackaged (compounded) bevacizumab, which does not have regulatory approval for intravitreous use. He emphasized that the medicolegal aspects of treatment-related adverse events have become increasingly expensive from a malpractice perspective, and he is concerned about isolated clusters of endophthalmitis events that were due to errors in repackaging.
Bressler NM, Glassman AR, Hutton DW. Controversies in Using Off-Label Intravitreous Bevacizumab for Patients With Diabetic Macular Edema—Reply. JAMA Ophthalmol. Published online February 02, 2017. doi:10.1001/jamaophthalmol.2016.5686